Metvixia FDA Approval History
Last updated by Judith Stewart, BPharm on Jan 27, 2021.
FDA Approved: Yes (Discontinued) (First approved July 27, 2004)
Brand name: Metvixia
Generic name: methyl aminolevulinate hydrochloride
Dosage form: Cream
Company: Galderma Laboratories, L.P.
Treatment for: Keratosis
Marketing Status: Discontinued
Metvixia (methyl aminolevulinate hydrochloride) is a porphyrin precursor used in combination with the Aktilite CL128 lamp for treatment of actinic keratoses.
Development timeline for Metvixia
| Date | Article |
|---|---|
| Jun 27, 2008 | Approval Photocure Receives FDA Approval for Metvixia/Aktilite Photodynamic Therapy |
| Jul 27, 2004 | Approval FDA Approves Metvixia for Actinic Keratosis |
| Jun 17, 2004 | U.S. New Drug Application Approval Expected for Metvix |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
